Phoenix, AZ — BeWell Family Care and Axsendo Clinical Research are proud to announce a new strategic partnership aimed at expanding access to cutting-edge clinical research opportunities in the Phoenix metro area. This collaboration brings together a respected provider of comprehensive family medicine with a leading clinical research organization to accelerate advancements in vaccines, immunology, metabolic health, and other high-impact therapeutic areas.

The partnership will empower both organizations to deploy a broader portfolio of clinical trials targeting some of today’s most pressing public health concerns—including emerging infectious diseases, chronic inflammation, obesity, and general medical conditions affecting diverse patient populations across Arizona.

“This partnership helps break down the barriers that have historically limited community access to clinical research,” said Dr. Frank LoVecchio, a nationally recognized emergency medicine physician and principal investigator. “Improving access to vaccine trials and other critical studies—especially among underserved populations—is not just a scientific priority, it’s a public health imperative. Research belongs in the community, and that’s exactly where we’re going.”

Through the integration of BeWell’s extensive patient network and Axsendo’s research infrastructure, the collaboration enhances operational capacity in one of the fastest-growing and therapeutically diverse research markets in the United States.

“This affiliation further complements an already well-rounded roster of therapeutically aligned specialists across Arizona,” said Dominic Doenges, Senior Vice President of Strategic Partnerships at Axsendo Clinical Research. “Phoenix continues to be a top-tier research market, and our partnership with BeWell Family Care strengthens our ability to execute with scale, precision, and a patient-first mindset.”

The partnership is set to begin enrolling participants in upcoming vaccine and metabolic trials this summer, with additional studies in infectious disease, cardiometabolic conditions, and primary care scheduled for late 2025.